Inhaled drug trial for lung scarring and heart strain halted midway
NCT ID NCT07181382
First seen Nov 01, 2025 · Last updated May 24, 2026 · Updated 30 times
Summary
This study tests an inhaled medication called seralutinib for people with high blood pressure in the lungs caused by scarring lung disease. The goal is to see if it helps patients walk farther and is safe over the long term. The trial planned to include 480 adults aged 18 to 80, but it is currently on hold.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PULMONARY HYPERTENSION ASSOCIATED WITH INTERSTITIAL LUNG DISEASE are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Hillel Yaffe Medical Center
Hadera, Israel
-
Pulmonary Associates of Richmond, Inc.
Richmond, Virginia, 23230, United States
-
University of New Mexico Health Sciences Center
Albuquerque, New Mexico, 87131, United States
-
Valley Advanced Lung Diseases Institute
Fresno, California, 93720, United States
Conditions
Explore the condition pages connected to this study.